Related Experiment Videos
Systemic fungal infections: diagnosis and treatment. I. Therapeutic agents
1University of Texas Health Science Center, San Antonio.
Abstract:
The story of antifungal agents has not been a stately procession from one development to another. For many years there was no agent of value for systemic mycoses. Then, with the advent of amphotericin B, we have had for over two decades essentially one effective agent, but a difficult drug to manipulate. The appearance of ketoconazole, the first systemic drug with relatively little toxicity, along with the appearance of ominous new forms of mycotic diseases, sharply stimulated interest in development of antifungal agents, initially in the azole classes, but now including a variety of other classes as well. We have very little idea how all of these drugs will act independently, and much less how they may interact together. Indeed, one of the most exciting developments is the return to amphotericin B, with repackaging in liposomes having created a markedly less toxic, and possibly much more potent, antifungal agent than "traditional" amphotericin B. There are indeed so many developments under way that the only safe conclusion that can be made is that within a few years current recommendations will be replaced by very different ones for most if not all of the major fungal pathogens.
Insights
New antifungal agents are rapidly developing, offering improved treatments for systemic fungal infections. Future recommendations for treating major fungal pathogens are expected to change significantly.
Area of Science:
- Medical Mycology
- Pharmacology
Background:
- Historically, effective systemic antifungal agents were limited, with amphotericin B being the primary option for decades.
- The emergence of ketoconazole and new fungal disease forms spurred the development of novel antifungal classes.
- Understanding drug interactions remains a significant challenge in antifungal therapy.
Purpose of the Study:
- To review the historical development and current landscape of antifungal agents.
- To highlight recent advancements in antifungal drug discovery and formulation.
- To anticipate future trends in the treatment of systemic mycoses.
Main Methods:
- Literature review of antifungal agent development.
- Analysis of historical and emerging antifungal drug classes.
- Discussion of novel formulations and their potential impact.
Main Results:
- Amphotericin B, despite its toxicity, has been a cornerstone treatment.
- Liposomal formulations of amphotericin B show reduced toxicity and potentially enhanced potency.
- Development is ongoing across various antifungal classes beyond azoles.
Conclusions:
- The field of antifungal agents is experiencing rapid innovation.
- Current treatment guidelines for fungal infections are likely to evolve.
- Further research into drug efficacy and interactions is crucial for optimizing patient care.